A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma.
Tomonari T, Shimose S, Saeki I, Tani J, Honma Y, Ito T, Takeuchi M, Naito T, Takeuchi Y, Sasaki R, Sasaki K, Hatanaka T, Kakizaki S, Kanayama Y, Naganuma A, Tanabe N, Tanaka H, Kawano Y, Sato Y, Nishina S, Miyaaki H, Otsuka M, Kawashima H, Harada M, Kobara H, Takami T, Kawaguchi T, Takayama T; Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group.
Tomonari T, et al. Among authors: kobara h.
Hepatol Res. 2025 Aug;55(8):1184-1192. doi: 10.1111/hepr.14212. Epub 2025 May 28.
Hepatol Res. 2025.
PMID: 40433908